Silencing METTL3 reduced the level of TNF receptor-associated factor 6 (Traf6) and inhibited the MAPK and NF-κB signaling pathways, thereby relieving dextran sodium sulfate (DSS)-induced IBD (126). The gene discussed is TRAF6; the disease is inflammatory bowel disease.